Related Experiment Video
Updated: Mar 7, 2026

A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System
Published on: August 30, 2019
Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut
Jonathan M Pitt1, Marie Vétizou1, Ivo Gomperts Boneca2
1Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM Unit U1015, Villejuif, France; Faculté de Médecine, Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France.
Abstract:
Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Microorganisms in Medicine and Therapeutics
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

